Ultimately, inhibiting Nox2 ROS production increased force and respiratory function in dystrophic diaphragm, establishing Nox2 as a potential therapeutic target in Duchenne muscular dystrophy. The gene discussed is CYBB; the disease is Duchenne muscular dystrophy.